Clinical Trials
8
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Safety and Tolerability of GTX-104 Compared With Oral Nimodipine in Patients With aSAH
- Conditions
- Aneurysmal Subarachnoid Hemorrhage (aSAH)
- Interventions
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Acasti Pharma Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT05995405
- Locations
- 🇺🇸
The University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Brain and Spine Neurological Institute, Phoenix, Arizona, United States
🇺🇸Community Regional Medical Center, Fresno, California, United States
Comparative Bioavailability of Betamethasone Oral Solution Metered Spray (GTX-102) in Healthy Subjects
- Conditions
- Ataxia Telangiectasia
- Interventions
- First Posted Date
- 2022-09-08
- Last Posted Date
- 2023-01-23
- Lead Sponsor
- Acasti Pharma Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05531890
- Locations
- 🇨🇦
Clinical Research Unit, Toronto, Ontario, Canada
Single-dose to Evaluate the Pharmacokinetics of GTX-101 and Subcutaneous Injectable Bupivacaine in Healthy Subjects
- Conditions
- Postherpetic Neuralgia
- Interventions
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2023-01-23
- Lead Sponsor
- Acasti Pharma Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05517486
- Locations
- 🇨🇦
Clinical Research Unit, Montréal, Canada
Relative Bioavailability of Intravenous GTX-104 Compared to Oral Nimodipine Capsules in Healthy Subjects
- Conditions
- Aneurysmal Subarachnoid Hemorrhage
- Interventions
- First Posted Date
- 2022-06-14
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Acasti Pharma Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT05418348
- Locations
- 🇨🇦
Clinical Research Unit, Montréal, Canada
A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1)
- First Posted Date
- 2018-01-12
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Acasti Pharma Inc.
- Target Recruit Count
- 256
- Registration Number
- NCT03398005
- Locations
- 🇺🇸
Research site, Kenosha, Wisconsin, United States
- Prev
- 1
- 2
- Next
News
Acasti Pharma's GTX-104 Trial for aSAH Completes Enrollment Early, Eyes 2026 Launch
Acasti Pharma's STRIVE-ON trial, evaluating GTX-104 for aneurysmal subarachnoid hemorrhage (aSAH), has completed enrollment ahead of schedule with approximately 100 participants.
Acasti Completes Enrollment in Phase 3 STRIVE-ON Trial of GTX-104 for aSAH
Acasti Pharma has completed patient enrollment in its Phase 3 STRIVE-ON trial evaluating GTX-104 for aneurysmal subarachnoid hemorrhage (aSAH).